Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis

摘要

Background Data from the Czech national registry were analysed retrospectively to describe treatment outcomes for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC). Methods A national registry containing anonymised individual data on patients treated with targeted therapies was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab combined with either FOLFOX regimen (n?=?1,218, 55.6%) or XELOX regimen (n?=?973, 44.4%) were included in the present analysis. Results No statistically significant difference in survival was observed between the two groups, with median overall survival (OS) of 27.0?months (95% confidence interval [CI] 24.6-29.5?months) and 30.6?months (95% CI 27.8-33.4?months) for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p?=?0.281). Median progression-free survival (PFS) was 11.4?months (95% CI 10.7-12.1?months) for FOLFOX/bevacizumab and 11.5?months (95% CI 10.8-12.3?months) for XELOX/bevacizumab (p?=?0.337). The number of metastatic sites was identified as the most significant predictor of PFS and, together with the presence/absence of metastatic disease at diagnosis, also for OS. Conclusions According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone chemotherapy regimen.